Brokerages Set Zenas BioPharma, Inc. (NASDAQ:ZBIO) Price Target at $44.29

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $44.2857.

Several research firms have recently commented on ZBIO. Guggenheim increased their price objective on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, March 16th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Morgan Stanley increased their price target on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Finally, Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th.

Zenas BioPharma Price Performance

NASDAQ:ZBIO opened at $28.76 on Friday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94. The stock’s 50-day simple moving average is $20.45 and its 200 day simple moving average is $22.76. The company has a market cap of $1.82 billion, a P/E ratio of -3.40 and a beta of -0.96. Zenas BioPharma has a 52-week low of $9.98 and a 52-week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. During the same period in the prior year, the company earned ($0.80) earnings per share. As a group, sell-side analysts forecast that Zenas BioPharma will post -4.47 EPS for the current fiscal year.

Insider Transactions at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was acquired at an average cost of $16.88 per share, for a total transaction of $1,012,800.00. Following the purchase, the chief executive officer owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have bought 120,000 shares of company stock valued at $2,080,000. Company insiders own 22.00% of the company’s stock.

Institutional Trading of Zenas BioPharma

Several institutional investors and hedge funds have recently bought and sold shares of ZBIO. Quarry LP raised its stake in Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the period. Russell Investments Group Ltd. acquired a new stake in Zenas BioPharma during the 3rd quarter valued at $30,000. GF Fund Management CO. LTD. bought a new position in Zenas BioPharma during the fourth quarter worth $38,000. BNP Paribas Financial Markets boosted its position in Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock worth $70,000 after purchasing an additional 1,716 shares during the period. Finally, CWM LLC increased its holdings in shares of Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares during the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.